Shares of ALI HEALTH (00241) have risen more than 3%.

As of the latest update, the stock is up 3.21% to HK$3.86, with a turnover of HK$225 million.

The price increase follows news that the company's medical AI product, Hydrogen Ion, served as the official AI academic assistant at the recent 20th Oriental Congress of Cardiology (OCC 2026) held in Shanghai.

Hydrogen Ion demonstrated its core capabilities at the event, including rapid evidence-based retrieval for complex cases, assistance in generating research proposals, and exploration into the compliance boundaries for AI in serious medical applications, gaining industry recognition.

Building on this, Hydrogen Ion has established a partnership with OCC 2026, serving as the official AI academic assistant and being fully integrated into the conference through digital channels.

ALI HEALTH recently officially launched the medical AI "Hydrogen Ion" in Hangzhou and announced an exclusive content partnership between Hydrogen Ion and the British BMJ Group.

This marks the beginning of ALI HEALTH's collaboration with top-tier international medical journals.

Previously, Hydrogen Ion has also established deep collaborations with several domestic authoritative academic institutions, including the Chinese Medical Association, People's Medical Publishing House, and the Chinese Anti-Cancer Association (CACA).